𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis

✍ Scribed by G. R. LICHTENSTEIN; B. BENGTSSON; L. HAPTEN-WHITE; P. RUTGEERTS

Book ID
108605517
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
93 KB
Volume
29
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of two dosing methods for ind
Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: A randomized placebo-controlled trial
✍ Arie Levine; Michal Kori; Gabriel Dinari; Efrat Broide; Ron Shaoul; Baruch Yerus 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 4 views

## Background: Oral budesonide has been found to be comparable to systemic corticosteroids in mild to moderately active crohn's disease (cd). remission rates in pediatric studies to date have been suboptimal (47%-55%), even though patients with colonic involvement were excluded in some studies. in

Methotrexate for maintenance of remissio
Methotrexate for maintenance of remission in chronic active Crohn's disease: Long-term single-center experience and meta-analysis of observational studies
✍ Johannes Hausmann; Kai Zabel; Eva Herrmann; Oliver Schröder 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB

Background: According to current guidelines methotrexate (MTX) should be considered as a second-line immunomodulator in patients with chronic active Crohn's disease (CD) if purine analogs are not tolerated or there is a lack of efficacy. However, its therapeutic role remains controversial to the pre